Welcome To Mast Therapeutics, Inc.

We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from
over two decades of clinical, nonclinical and manufacturing experience with purified and non-
purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-
threatening diseases with significant unmet needs.


      >> Read the latest CEO Blog entry


Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more


Click here to learn more about our lead product candidate, MST-188, as well as our other technologies. read more

Clinical Trials

We have initiated a Phase 3 clinical study of MST-188 for the treatment of sickle cell disease. See our Clinical Trials page for more info. read more